FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588158858> ?p ?o ?g. }

• W2588158858 abstract "Abstract Abstract 4522 Introduction: BuCy has been regarded as a standard myeloablative regimen for allogeneic stem cell transplantation (allo-SCT). However, given the concern regarding the use of two alkylating agents which potentially cause unwished life-threatening adverse effects, new myeloablative regimens including FluBu4 have been introduced. And there has been several reports suggesting that FluBu may provide more effective control of hematologic malignancy with less toxicity than BuCy. Methods: Between Apr 1996 and June 2012, 111 patients received allo-SCT conditioned with BuCy2 or BuCy4, and 67 patients received FluBu4 conditioning in Samsung Meidcal Center. After excluding 31 patients who used oral busulfan in BuCy regimen, we retrospectively compared clinical outcome between 80 BuCy patients and 67 FluBu4 patients. Results: The median age at allo-SCT was younger in BuCy group compared to FluBu4 group (BuCy=36.5 years; FluBu4=46 years). AML was the most common disease comprising 45% of BuCy and 62.7% of FluBu4, and sibling donor was predominant in both groups (BuCy=71.3%; FluBu4=80.6%, p=0.189). Regarding the stem cell source, all FluBu4 patients received allo-SCT with peripheral blood whereas 35% of BuCy patients underwent allo-SCT with BM source (p<0.001), reflecting changes in institutional strategy for allo-SCT, BuCy to FluBu4 as conditioning regimen and BM to PB as a source of SCT. After allo-SCT, engraftment days of neutrophil and platelet were not different by conditioning regimen. Veno-occlusive disease (VOD) was more frequently observed in BuCy regimen (16.3%) compared to FluBu4 (7.5%) although it did not reach statistical significance (p=0.106). The incidence of acute GVHD (aGVHD) was similar in both groups with a 23.8% and a 22.4% of incidence in BuCy and FluBu4 regimen, respectively. In regard to chronic GVHD, FluBu4 rather than BuCy patients showed higher incidence of chronic GVHD (cGVHD) with statistical significance (BuCy=60%; FluBu4=77.4%, p=0.03). With median follow up period of 55.9 months, 4 year OS was 53.6% in BuCy group and 46.3% in FluBu4 group. Leukemia free survival (LFS) at 4 year were 61.2% and 71.8% in BuCy and FluBu4 patients, and the survival curves of the two conditioning groups did not show significant difference in OS and LFS (OS, p=0.2992; RFS, p=0.2307). In multivariate analysis, cGVHD showed survival benefit for OS (p<0.001, HR=0,313) and RFS (P<0.001, HR=0.282) whereas sex, age, donor type, source of SCT, and conditioning regimen did not attain significant influence on OS and LFS. Conclusion: Although substantial limitations regarding heterogeneous distribution of diseases and significant differences in the source of the SCT according to each conditioning group preclude direct comparison between regimens, the result of this study suggested that it is not clear that FluBu4 offered a significant advantage over the BuCy as a conditioning regimen for allo SCT. Disclosures: Jang: Alexion Pharmaceutical Company: Honoraria, Membership on an entity's Board of Directors or advisory committees." @default.
• W2588158858 created "2017-02-24" @default.
• W2588158858 creator A5013311116 @default.
• W2588158858 creator A5015112169 @default.
• W2588158858 creator A5022259689 @default.
• W2588158858 creator A5041004365 @default.
• W2588158858 creator A5043919045 @default.
• W2588158858 creator A5062157181 @default.
• W2588158858 creator A5067818349 @default.
• W2588158858 creator A5078664468 @default.
• W2588158858 creator A5088244081 @default.
• W2588158858 date "2012-11-16" @default.
• W2588158858 modified "2023-10-08" @default.
• W2588158858 title "Comparison of BuCy (Busulfan plus Cyclophosphamide) Versus FluBu4 (Fludarabine plus Busulfan) As a Conditioning Regimen for Allogeneic Stem Cell Transplantation" @default.
• W2588158858 doi "https://doi.org/10.1182/blood.v120.21.4522.4522" @default.
• W2588158858 hasPublicationYear "2012" @default.
• W2588158858 type Work @default.
• W2588158858 sameAs 2588158858 @default.
• W2588158858 citedByCount "0" @default.
• W2588158858 crossrefType "journal-article" @default.
• W2588158858 hasAuthorship W2588158858A5013311116 @default.
• W2588158858 hasAuthorship W2588158858A5015112169 @default.
• W2588158858 hasAuthorship W2588158858A5022259689 @default.
• W2588158858 hasAuthorship W2588158858A5041004365 @default.
• W2588158858 hasAuthorship W2588158858A5043919045 @default.
• W2588158858 hasAuthorship W2588158858A5062157181 @default.
• W2588158858 hasAuthorship W2588158858A5067818349 @default.
• W2588158858 hasAuthorship W2588158858A5078664468 @default.
• W2588158858 hasAuthorship W2588158858A5088244081 @default.
• W2588158858 hasConcept C126322002 @default.
• W2588158858 hasConcept C141071460 @default.
• W2588158858 hasConcept C197934379 @default.
• W2588158858 hasConcept C2776694085 @default.
• W2588158858 hasConcept C2776755627 @default.
• W2588158858 hasConcept C2777408962 @default.
• W2588158858 hasConcept C2779263901 @default.
• W2588158858 hasConcept C2780611847 @default.
• W2588158858 hasConcept C2781413609 @default.
• W2588158858 hasConcept C2911091166 @default.
• W2588158858 hasConcept C71924100 @default.
• W2588158858 hasConcept C90924648 @default.
• W2588158858 hasConceptScore W2588158858C126322002 @default.
• W2588158858 hasConceptScore W2588158858C141071460 @default.
• W2588158858 hasConceptScore W2588158858C197934379 @default.
• W2588158858 hasConceptScore W2588158858C2776694085 @default.
• W2588158858 hasConceptScore W2588158858C2776755627 @default.
• W2588158858 hasConceptScore W2588158858C2777408962 @default.
• W2588158858 hasConceptScore W2588158858C2779263901 @default.
• W2588158858 hasConceptScore W2588158858C2780611847 @default.
• W2588158858 hasConceptScore W2588158858C2781413609 @default.
• W2588158858 hasConceptScore W2588158858C2911091166 @default.
• W2588158858 hasConceptScore W2588158858C71924100 @default.
• W2588158858 hasConceptScore W2588158858C90924648 @default.
• W2588158858 hasLocation W25881588581 @default.
• W2588158858 hasOpenAccess W2588158858 @default.
• W2588158858 hasPrimaryLocation W25881588581 @default.
• W2588158858 hasRelatedWork W2088844333 @default.
• W2588158858 hasRelatedWork W2360416162 @default.
• W2588158858 hasRelatedWork W2465952919 @default.
• W2588158858 hasRelatedWork W2493352844 @default.
• W2588158858 hasRelatedWork W2509833577 @default.
• W2588158858 hasRelatedWork W2549226283 @default.
• W2588158858 hasRelatedWork W2572544796 @default.
• W2588158858 hasRelatedWork W2578093011 @default.
• W2588158858 hasRelatedWork W2583802469 @default.
• W2588158858 hasRelatedWork W2744357014 @default.
• W2588158858 hasRelatedWork W2790219819 @default.
• W2588158858 hasRelatedWork W2798146671 @default.
• W2588158858 hasRelatedWork W2805882440 @default.
• W2588158858 hasRelatedWork W2884744511 @default.
• W2588158858 hasRelatedWork W2912225957 @default.
• W2588158858 hasRelatedWork W2978438790 @default.
• W2588158858 hasRelatedWork W2986725086 @default.
• W2588158858 hasRelatedWork W3093636258 @default.
• W2588158858 hasRelatedWork W3136949719 @default.
• W2588158858 hasRelatedWork W3170047792 @default.
• W2588158858 isParatext "false" @default.
• W2588158858 isRetracted "false" @default.
• W2588158858 magId "2588158858" @default.
• W2588158858 workType "article" @default.